The present disclosure relates to methods of treating cancers that are responsive to antimitotic anti-cancer agents. The methods involve the use of at least one antimitotic anti-cancer agents and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti-cancer agent(s).